APT Medical (688617) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 reached RMB 704.08 million, up 24.78% year-over-year, with net profit attributable to shareholders rising 25.27% to RMB 229.44 million.

• Operating cash flow increased 15.32% year-over-year to RMB 192.20 million.

• R&D investment rose to RMB 95.38 million, accounting for 13.55% of revenue, up 1.89 percentage points year-over-year.

Financial highlights

• Gross margin improved as revenue outpaced cost growth; operating costs were RMB 194.14 million versus RMB 151.86 million a year ago.

• Basic EPS was RMB 1.64, up 26.15% year-over-year; diluted EPS was RMB 1.63.

• Total assets at quarter-end were RMB 3.43 billion, down 6.06% from year-end 2025.

• Net assets attributable to shareholders decreased 3.87% to RMB 2.97 billion.

Key financial ratios and metrics

• Weighted average ROE for the quarter was 7.54%, up 0.44 percentage points year-over-year.

• R&D spending as a percentage of revenue increased to 13.55% from 11.66% year-over-year.